2. Search Result
Search Result
Results for "

hydrolase

" in MCE Product Catalog:

153

Inhibitors & Agonists

3

Fluorescent Dye

17

Biochemical Assay Reagents

4

Peptides

13

Natural
Products

76

Recombinant Proteins

1

Isotope-Labeled Compounds

1

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas
  • HY-153433
    Serine Hydrolase inhibitor-21

    		Others Neurological Disease
    Serine Hydrolase inhibitor-21 (compound 8), a pyridine, is a serine hydrolase inhibitor with a Ki of 429 nM for BuChE. Serine Hydrolase inhibitor-21 has the potential for Alzheimer's disease research.
  • HY-E70042
    Nucleoside hydrolase (IAGNH)

    		Endogenous Metabolite Metabolic Disease
    Nucleoside hydrolase (IAGNH) is a glycosidase. Nucleoside hydrolase (IAGNH) catalyzes the cleavage of the N-glycosidic bond in nucleosides to enable the recycling of the nucleobases and Rib.
  • HY-126326
    SWE101

    		Epoxide Hydrolase Metabolic Disease
    SWE101 (compound 22 b) is a potent soluble epoxide hydrolase (sEH)-P inhibitor with IC50s of 4 μM and 2.8 μM for human and rat sEH-P, respectively. SWE101 does not inhibit neither hydrolase nor phosphatase activity of the mouse sEH.
  • HY-110138
    PDP-EA

    		Others Others
    PDP-EA is a compound that increases the amidohydrolase activity of FAAH (fatty acid amide hydrolase).
  • HY-U00453
    Soluble epoxide hydrolase inhibitor

    		Epoxide Hydrolase Metabolic Disease Cardiovascular Disease
    Soluble epoxide hydrolase inhibitor is an inhibitor of soluble epoxide hydrolase, and inhibits human soluble epoxide hydrolase (h-sEH) with pIC50 of 8.4, extracted from patent WO 2010096722 A1, example 57.
  • HY-135886
    2-Nitrophenyl α-D-galactopyranoside

    		Others Others
    2-Nitrophenyl α-D-galactopyranoside, a nitrophenyl derivative, is a substrate to test for hydrolytic activity of glycosyl hydrolase.
  • HY-103463
    SA57

    		FAAH MAGL Neurological Disease
    SA57 is a potent, selective FAAH inhibitor with IC50s of 3.2 nM and 1.9 nM for mouse and human FAAH. SA57 also inhibits the 2-arachidonoylglycerol hydrolases MAGL (IC50s of 410 nM and 1.4 μM for mouse and human MAGL) and mouse α/β-hydrolase domain-containing protein 6 (mABHD6; IC50 of 850 nM), but not other brain serine hydrolases.
  • HY-148000
    sEH inhibitor-6

    		Epoxide Hydrolase Inflammation/Immunology Cardiovascular Disease
    sEH inhibitor-6 (Compound 3g) is a soluble epoxide hydrolase (sEH) inhibitor with an IC50 of 0.5 nM.
  • HY-139654
    α/β-Hydrolase-IN-1

    		Others Infection
    α/β-Hydrolase-IN-1 exhibits the best-in-class MICs of 50 μM (25 μg/mL) and 16 μM (8.4 μg/mL) against M. smegmatis and M. tuberculosis H37Ra, respectively.
  • HY-103226
    SC-57461A

    		Aminopeptidase Inflammation/Immunology
    SC-57461A is a potent, orally active, nonpeptide, and selective inhibitor of Leukotriene A4 (LTA4) hydrolase with IC50s of 2.5 nM, 3 nM, and 23 nM for recombinant human, mouse, and rat LTA4 hydrolase, respectively.
  • HY-128424
    4'-Deoxyphlorizin

    		Others Metabolic Disease
    4'-Deoxyphlorizin is an inhibitor of the glucose transport system. 4'-Deoxyphlorizi has good phlorizin hydrolase inhibitory activity with the Km value of 0.59 nM and the Ki value of 0.33 nM, respectively.
  • HY-120494
    sEH inhibitor-1

    		Epoxide Hydrolase Inflammation/Immunology
    sEH inhibitor-1 (compound TCPU ) is a potent and oral active inhibitor of sEH (soluble epoxide hydrolase) with IC50s of 0.4 and 5.3 nM in human and murine, respectively.
  • HY-P2936
    Sphingomyelin phosphodiesterase

    		Phospholipase Metabolic Disease
    Sphingomyelin phosphodiesterase, a hydrolase, is involved in the sphingomyelin metabolism process. Sphingomyelin phosphodiesterase hydrolyzes the conversion of sphingomyelin to phosphocholine and ceramide. Sphingomyelin phosphodiesterase also plays an important role in cellular differentiation, various immune and inflammatory responses, and intracellular cholesterol trafficking and metabolism.
  • HY-151621
    sEH inhibitor-13

    		Epoxide Hydrolase Inflammation/Immunology
    sEH inhibitor-13 (compound 43) is a potent soluble epoxide hydrolase (sEH) inhibitor, with an IC50 of 0.4 μM.
  • HY-18544
    AA38-3

    		MAGL FAAH Metabolic Disease
    AA38-3 is a serine hydrolase (SH) inhibitor. AA38-3 can inhibit three SHs, ABHD6, ABHD11, and FAAH.
  • HY-10865
    LY2183240
    2 Publications Verification

    		 FAAH Autophagy Neurological Disease
    LY2183240 is a highly potent blocker of anandamide uptake (IC50= 270 pM; Ki=540 nM). LY2183240 is a potent, covalent inhibitor of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) with an IC50 of 12.4 nM. LY2183240 inactivates FAAH by carbamylation of the enzyme's serine nucleophile. LY2183240 also inhibits several other brain serine hydrolases with IC50s of 5.3, 0.09, 8.2 nM for MAG lipase, bh6 and KIAA1363, respectively .
  • HY-124063
    BI-1935

    		Epoxide Hydrolase Cardiovascular Disease
    BI-1935 is a potent soluble epoxide hydrolase (sEH) inhibitor. BI-1935 can be used for the research of cardiovascular disease.
  • HY-108570
    AUDA

    		Epoxide Hydrolase Inflammation/Immunology
    AUDA (compound 43) is a potent soluble epoxide hydrolase (sEH) inhibitor with IC50s of 18 and 69 nM for the mouse and human sEH, respectively. AUDA has anti-inflammatory activity.
  • HY-118795
    SC-22716

    		Aminopeptidase Inflammation/Immunology
    SC-22716 is a potent, competitive, reversible inhibitor of human LTA4 hydrolase, with an IC50 of 0.20 µM. SC-22716 has potential for the research of inflammatory bowel disease (IBD) and psoriasis.
  • HY-146696
    mEH-IN-1

    		Epoxide Hydrolase Cancer Neurological Disease Cardiovascular Disease
    mEH-IN-1 (Compound 62) is a potent microsomal epoxide hydrolase (mEH) inhibitor with the IC50 of 2.2 nM. The mEH is a mammalian α/β-fold hydrolase enzyme, expressed in almost all tissues, hydrolyzes a wide range of epoxide containing molecules. The mEH is mainly localized in the endoplasmic reticulum (ER) of eukaryotic cells. mEH-IN-1 can be used for the research of preeclampsia, hypercholanemia and cancer.
  • HY-135653
    EC5026

    BPN-19186

    		 Epoxide Hydrolase Neurological Disease
    EC5026 (BPN-19186) is a first-in-class, non-opioid and orally active soluble Epoxide Hydrolase (sEH) inhibitor. EC5026 shows efficacy for inflammatory and neuropathic pain.
  • HY-113862
    PHOME

    		Fluorescent Dye Others
    PHOME is a fluorogenic substrate for sEH. sEH can hydrolyze the epoxy ring in the PHOME substrate. PHOME can be used for fluorescent epoxide hydrolase assay (extracted from patent CN113402447A).
  • HY-137298
    LTA4H-IN-1

    		Aminopeptidase Inflammation/Immunology
    LTA4H-IN-1 is a potent inhibitor of leukotriene A4 hydrolase (LTA4H) extracted from patent WO2015092740A1, example 29, has an IC50 of 2 nM. LTA4H-IN-1 can be used for the research of inflammatory and autoimmune disorders.
  • HY-135659
    BSH-IN-1

    		Bacterial Infection
    BSH-IN-1 is a potent and covalent inhibitor of gut bacterial recombinant bile salt hydrolases (BSHs) with IC50s of 108 nM and 427 nM for B. longum BSH (Gram positive) and B. theta BSH (Gram negative), respectively.
  • HY-113974
    trans-AUCB
    1 Publications Verification

    t-AUCB

    		 Epoxide Hydrolase Cancer
    trans-AUCB (t-AUCB) is a potent, orally active and selective soluble epoxide hydrolase (sEH) inhibitor with IC50s of 1.3 nM, 8 nM, 8 nM for hsEH, mouse sEH and rat sEH, respectively. trans-AUCB has anti-glioma activity.
  • HY-W403075
    N-(3-Methoxybenzyl)stearamide

    		Epoxide Hydrolase Inflammation/Immunology Neurological Disease
    N-(3-Methoxybenzyl)stearamide a natural product from Lepidium meyenii (Maca), inhibits human and mouse soluble epoxide hydrolase (hsEH and msEH) with IC50s of 0.001 and <0.001 μg/nM, respectively.
  • HY-130836
    LpxH-IN-AZ1

    		Bacterial Infection
    LpxH-IN-AZ1, a sulfonyl piperazine compound, is a potent UDP-2,3-diacylglucosamine pyrophosphate hydrolase LpxH inhibitor. LpxH-IN-AZ1 is a potent inhibitor of Klebsiella pneumoniae LpxH with IC50 of 0.36 μM .
  • HY-125254
    LEI110

    		Others Infection Metabolic Disease
    LEI110 is a potent, selective and cell-permeable pan-inhibitor of the HRASLS family of thiol hydrolases. LEI110 inhibits PLA2G16, HRASLS2, RARRES3 and iNAT, with pIC50 values of 7.0, 6.8, 6.8, and 7.6, respectively. LEI110 reduces cellular arachidonic acid levels and oleic acid-induced lipolysis in HepG2 cells.
  • HY-130838
    JH-LPH-33

    		Bacterial Infection
    JH-LPH-33, a sulfonyl piperazine analog, is a potent UDP-2,3-diacylglucosamine pyrophosphate hydrolase LpxH inhibitor. JH-LPH-33 displays outstanding antibiotic activity with a MIC value of 0.66 μg/mL.
  • HY-130837
    JH-LPH-28

    		Bacterial Infection
    JH-LPH-28, a sulfonyl piperazine analog, is a potent UDP-2,3-diacylglucosamine pyrophosphate hydrolase LpxH inhibitor. JH-LPH-28 displays outstanding antibiotic activity with a MIC value of 0.83 μg/mL.
  • HY-118960
    BMS-199264 hydrochloride

    		ATP Synthase Cardiovascular Disease
    BMS-199264 hydrochloride is an inhibitor of F1F0 ATP hydrolase (IC50=0.5 μM) without inhibitory effect on F1F0 ATP synthase. BMS-199264 hydrochloride selectively inhibits ATP decline during ischemia to reduces cardiac necrosis. BMS-199264 hydrochloride also enhances the recovery of contractile function following reperfusion.
  • HY-N7062
    JNJ-1661010

    Takeda-25

    		 FAAH Neurological Disease
    JNJ-1661010 (Takeda-25) a potent and selective fatty acid amide hydrolase (FAAH) inhibitor with IC50s of 34 and 33 nM for rat FAAH and human FAAH, respectively. JNJ-1661010 can cross the blood-brain barrier and used as broad-spectrum analgesics.
  • HY-103462
    TC-F2

    		FAAH Cancer Inflammation/Immunology Metabolic Disease
    TC-F2 is a reversible non-covalent binding inhibitor of fatty acid amide hydrolase (FAAH) with an IC50 of 28 nM. FAAH is involved in many human diseases, particularly cancer, pain and inflammation as well as neurological, metabolic and cardiovascular disorders.
  • HY-14380
    PF-3845
    1 Publications Verification

    		 FAAH Autophagy Inflammation/Immunology Cancer
    PF-3845 is a potent, selective, irreversible and orally active inhibitor of fatty acid amide hydrolase (FAAH), with a Ki of 0.23 µM. PF-3845 is a covalent inhibitor that carbamylates FAAH's serine nucleophile. PF-3845 can reduce pain sensation, inflammation, and anxiety/depression without substantial effects on motility or cognition.
  • HY-18638
    TCID
    1 Publications Verification

    4,5,6,7-Tetrachloroindan-1,3-dione

    		 Deubiquitinase Neurological Disease
    TCID (4,5,6,7-Tetrachloroindan-1,3-dione) is a potent and selective neuronal ubiquitin C-terminal hydrolase (UCH-L3) inhibitor with an IC50 of 0.6 μM. TCID diminishes glycine transporter GlyT2 ubiquitination in brainstem and spinal cord primary neurons.
  • HY-121538
    CUDA

    		Epoxide Hydrolase PPAR Cardiovascular Disease
    CUDA is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC50s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively. CUDA selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA may be valuable for the research of cardiovascular disease.
  • HY-145833A
    sEH/AChE-IN-4

    		Epoxide Hydrolase Cholinesterase (ChE) Cancer Neurological Disease
    sEH/AChE-IN-4 (compound (+)-15) is a potent and BBB-penetrated dual inhibitor of sEH (soluble epoxide hydrolase) and AChE (acetylcholinesterase), with IC50 values of 3.1 nM (hsEH), 1660 nM (hAChE), 179 nM (hBChE, human butyrylcholinesterase), 14.5 nM (msEH), and 102 nM (mAChE), respectively.
  • HY-111151
    AR-9281

    APAU

    		 Epoxide Hydrolase Infection Metabolic Disease
    AR9281 (APAU) is a potent, selective and orally active soluble epoxide hydrolase (s-EH) inhibitor. AR-9281 can inhibits human sEH (HsEH) and murine sEH (MsEH) with IC50 values of 13.8 nM and 1.7 nM, respectively. AR9281 can be used for the research of inflammation, hypertension and type 2 diabetes.
  • HY-145833
    sEH/AChE-IN-3

    		Epoxide Hydrolase Cholinesterase (ChE) Cancer Neurological Disease
    sEH/AChE-IN-3 (compound (−)-15) is a potent and BBB-penetrated dual inhibitor of sEH (soluble epoxide hydrolase) and AChE (acetylcholinesterase), with IC50 values of 0.4 nM (hsEH), 1.94 nM (hAChE), 615 (hBChE, human butyrylcholinesterase), 4.3 nM (msEH), and 2.61 nM (mAChE), respectively.
  • HY-D1726
    8RK59

    		Deubiquitinase Cancer
    8RK59, a Bodipy probe, is a potent UCHL1 (ubiquitin C-terminal hydrolase L1) inhibitor, with an IC50 close to 1 μM. 8RK59 could penetrate and label living cells. BodipyFL-alkyne is coupled to the azide of 8RK64 (HY-148254) using copper(I)-mediated click chemistry, resulting in compound 8RK59.
  • HY-110148
    WWL113

    		Others Metabolic Disease
    WWL113 is a selective and orally active Ces3 and Ces1f inhibitor, with IC50 values of 120 nM and 100 nM for Ces3 and Ces1f, respectively. WWL113 appears to show excellent selectivity for the 60-kDa serine hydrolase (or hydrolases).
  • HY-P2741
    Maltose phosphorylase

    E.C. 2.4.1.8

    		 Endogenous Metabolite Metabolic Disease
    Maltose phosphorylase is a dimerase which catalyzes the transformation of maltose and inorganic phosphate into β-D-glucose-1-phosphate and glucose. Maltose phosphorylases have been classified in family 65 of the glycoside hydrolases.
  • HY-W027340
    ARM1

    4BSA

    		 Aminopeptidase Epoxide Hydrolase Cancer
    ARM1 (4BSA) is a potent aminopeptidase and epoxide hydrolase inhibitor. ARM1 shows aminopeptidase inhibitory activity with an IC50 7.61 µM and epoxide hydrolase inhibitory activity with an IC50 12.4 µM.
  • HY-128035
    ML-211

    		Phospholipase MAGL
    ML-211 is a carbamate-based dual inhibitor of acyl-protein thioesterase 1 (APT1)/lysophospholipase 1 (LYPLA1) (IC50=17 nM) and LYPLA2 (IC50=30 nM). ML-211 also inhibits theserine hydrolase ABHD11 with an IC50 value of 10 nM but is ≥ 50-fold selective for LYPLA in a panel of 20 additional serine hydrolases.
  • HY-B2117
    Valpromide

    		Epoxide Hydrolase HSV Infection Neurological Disease
    Valpromide is an amide derivative of valproic acid and inhibits human epoxide hydrolase.
  • HY-120300
    UCM710

    		Cannabinoid Receptor Metabolic Disease
    UCM710 is an endocannabinoid (eCB) hydrolysis inhibitor that increases the levels of N-arachidonoyl ethanolamine and 2-arachidonoylglycerol in neurons. UCM710 inhibits fatty acid amide hydrolase and α/β-hydrolase domain 6, but not monoacylglycerol lipase.
  • HY-152251
    CB2R/FAAH modulator-1

    		Cannabinoid Receptor FAAH Inflammation/Immunology
    CB2R/FAAH modulator-1 is a cannabinoid type 2 receptor (CB2R) full agonist with Kis of 14.8 nM and 241.3 nM for CB2R and CB1R, respectively. CB2R/FAAH modulator-1 is a fatty acid amide hydrolase (FAAH) inhibitor with an IC50 of 4 μM. CB2R/FAAH modulator-1 decreases pro-inflammatory and increases anti-inflammatory cytokines production.
  • HY-U00240
    SA72

    		FAAH Autophagy Neurological Disease
    SA72 is a highly selective fatty acid amide hydrolase (FAAH) inhibitor.
  • HY-101457
    JZP-430

    		MAGL Metabolic Disease
    JZP-430 is a potent, highly selective, irreversible inhibitor of α/β-hydrolase domain 6 (ABHD6) with an IC50 of 44 nM, exhibits ~230-fold selectivity over fatty acid amide hydrolase (FAAH) and lysosomal acid lipase (LAL).
  • HY-N0861
    Ikarisoside F

    Ikarisoside-F; Icarisoside-F

    		 Others Cancer
    Ikarisoside F is a flavonol glycoside from Vancouveria hexandra; could bind to AdoHcy hydrolase.
  • HY-144738
    Dual FAAH/sEH-IN-1

    		Epoxide Hydrolase FAAH Inflammation/Immunology
    Dual FAAH/sEH-IN-1 (compound 3) is a high affinity dual sEH (soluble epoxide hydrolase) and FAAH (fatty acid amide hydrolase) inhibitor, with IC50 values of 9.6 and 7 nM, respectively. Dual FAAH/sEH-IN-1 shows antinociception against the inflammatory phase.
  • HY-16194
    Emiglitate

    BAY o 1248

    		 Others Metabolic Disease
    Emiglitate (BAY o 1248) is a potent, selective and competitive inhibitor of α-glucoside hydrolase.
  • HY-18080
    SA 47
    1 Publications Verification

    		 FAAH Autophagy Metabolic Disease
    SA 47 is a selective and potent inhibitor of fatty acid amide hydrolase (FAAH) and carbamate.
  • HY-148240
    JNJ-65355394

    		Others Neurological Disease
    JNJ-65355394 (Compound 28) is an O-GlcNAc hydrolase (OGA) inhibitor.
  • HY-107582
    JW480

    		Others Cancer
    JW480 is a potent and selective inhibitor of a serine hydrolase enzyme KIAA1363.
  • HY-N2365
    N-Benzylpalmitamide
    1 Publications Verification

    N-Benzylhexadecanamide; Macamide 1

    		 FAAH Autophagy Others
    N-Benzylpalmitamide is a macamide isolated from Lepidium meyenii, acts as an inhibitor of fatty acid amide hydrolase (FAAH).
  • HY-17625
    Acebilustat

    CTX-4430

    		 Aminopeptidase Inflammation/Immunology
    Acebilustat (CTX-4430) is a leukotriene A4 hydrolase inhibitor, used for an oral antiinflammatory agent.
  • HY-112639
    Aristeromycin

    		Bacterial Cancer Infection
    Aristeromycin, an adenosine analog, is an antibiotic and a potent S-adenosylhomocysteine hydrolase (AHCY) inhibitor.
  • HY-18522
    AA26-9

    		Phospholipase Metabolic Disease
    AA26-9 is a potent and broad spectrum serine hydrolase inhibitor. AA26-9 targets included serine peptidases, lipases, amidases, esterases, and thioesterases. AA26-9 shows inhibitory activity against approximately 1/3 of the 40+ serine hydrolases detected in immortalized T cell lines .
  • HY-100337
    WWL70
    2 Publications Verification

    		 MAGL Neurological Disease
    WWL70 is a selective alpha/beta hydrolase domain 6 (ABHD6) inhibitor with an IC50 of 70 nM.
  • HY-B0134B
    Bestatin trifluoroacetate

    Ubenimex trifluoroacetate

    		 Aminopeptidase Bacterial Antibiotic Cancer Infection
    Bestatin trifluoroacetate is an inhibitor of CD13 (Aminopeptidase N)/APN and leukotriene A4 hydrolase, used for cancer research.
  • HY-B0134A
    Bestatin hydrochloride
    5+ Cited Publications

    Ubenimex hydrochloride

    		 Aminopeptidase Bacterial Antibiotic Cancer Infection
    Bestatin hydrochloride is an inhibitor of CD13 (Aminopeptidase N)/APN and leukotriene A4 hydrolase, used for cancer research.
  • HY-114266
    UC-1728

    t-TUCB

    		 Epoxide Hydrolase Inflammation/Immunology Cardiovascular Disease
    UC-1728 is a potent rabbit soluble epoxide hydrolase (sEH) inhibitor, with an IC50 of 2 nM on rabbit liver.
  • HY-152152
    JZP-MA-13

    		MAGL Neurological Disease
    JZP-MA-13 is a selective α/β-hydrolase domain 6 (ABHD6) inhibitor with an IC50 of 392 nM. JZP-MA-13 shows no inhibition of MAGL, ABHD12, FAAH, or other serine hydrolases. JZP-MA-13 is a positron emission tomography (PET) ligand for in vivo imaging of the ABHD6.
  • HY-148136
    sEH inhibitor-7

    		Epoxide Hydrolase Inflammation/Immunology
    sEH inhibitor-7 (compound c-2) is an inhibitor of soluble epoxide hydrolase (sEH) with IC50s of 0.15 μM (mouse sEH) and 6.2 μM (human sEH), respectively. soluble epoxide hydrolase (sEH) plays an important role in the metabolism of endogenous chemical mediators involved in the regulation of blood pressure and inflammation.
  • HY-101294
    TPPU
    5+ Cited Publications

    		 Epoxide Hydrolase Inflammation/Immunology
    TPPU is a soluble epoxide hydrolase (sEH) inhibitor with IC50 values of 37 and 3.7 nM for monkey and human sEH, respectively.
  • HY-U00452
    PL553

    		Fluorescent Dye Inflammation/Immunology
    PL553 is a specific and high-affinity fluorigenic substrate of Leukotriene A4 hydrolase, with a λmax of 210 nm and λem of 410 nm.
  • HY-W004291
    Methyl arachidate

    Methyl eicosanoate

    		 Aminopeptidase Inflammation/Immunology
    Methyl arachidate (Methyl eicosanoate), a natural compound, is a leukotriene A4 hydrolase (LTA4H) inhibitor.
  • HY-110390
    GR148672X

    		Others Cardiovascular Disease
    GR148672X is a triacyglycerol hydrolase (TGH) inhibitor with an IC50 of 4 nM extracted from patent WO 2001016358 A2.
  • HY-12814A
    TH588 hydrochloride

    		DNA/RNA Synthesis Cancer
    TH588 hydrochloride is first-in-class nudix hydrolase family inhibitor that potently and selectively engage and inhibit the MTH1 (IC50= 5 nM).
  • HY-12814
    TH588
    1 Publications Verification

    		 DNA/RNA Synthesis Cancer
    TH588 is first-in-class nudix hydrolase family inhibitor that potently and selectively engage and inhibit the MTH1 (IC50= 5 nM).
  • HY-19740
    BIA 10-2474
    1 Publications Verification

    		 FAAH Autophagy Neurological Disease
    BIA 10-2474 is an inhibitor of fatty acid amide hydrolase (FAAH) with IC50 values of 50 to 70mg/kg in various rat brain regions.
  • HY-111389
    FAAH-IN-1

    		FAAH Autophagy Metabolic Disease
    FAAH-IN-1 is a fatty acid amide hydrolase (FAAH) inhibitor, with IC50s of 145 nM and 650 nM for rat and human FAAH, respectively.
  • HY-10825
    DG051

    		Aminopeptidase Metabolic Disease
    DG051 is a potent leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis in the enzyme assay with an IC50=47 nM.
  • HY-10862
    FAAH inhibitor 1

    Benzothiazole analog 3

    		 FAAH Autophagy Cancer
    FAAH inhibitor 1 (Benzothiazole analog 3) is a potent fatty acid amide hydrolase (FAAH) inhibitor with an IC50 of 18±8 nM.
  • HY-P2893
    Creatinase

    Creatine amidohydrolase

    		 Endogenous Metabolite Others
    Creatinase (Creatine amidohydrolase) is a hydrolase that catalyzes the hydrolysis of creatine into sarcosine and urea, and plays an important role in the enzymatic determination of creatinine concentration.
  • HY-147733
    sEH inhibitor-5

    		Cholinesterase (ChE) Inflammation/Immunology
    sEH inhibitor-5 (compound D016) is a potent sEH (soluble epoxide hydrolase) inhibitor with an IC50 value of 0.1 nM.
  • HY-146643
    sEH inhibitor-3

    		Epoxide Hydrolase Neurological Disease
    sEH inhibitor-3 (compound 35) is a potent and orally active soluble epoxide hydrolase (sEH) inhibitor with a Ki of 0.75 nM for human sEH.
  • HY-N3033
    N-​Benzyllinolenamide
    1 Publications Verification

    		 FAAH Autophagy Metabolic Disease
    N-​Benzyllinolenamide is a natural macamide isolated from Lepidium meyenii, acts as an inhibitor of fatty acid amide hydrolase (FAAH) with an IC50 of 41.8 μM.
  • HY-W013332
    3-Deazaadenosine
    5+ Cited Publications

    		 HIV Infection Inflammation/Immunology
    3-Deazaadenosine is an inhibitor of S-adenosylhomocysteine hydrolase, with a Ki of 3.9 µM; 3-Deazaadenosine has anti-inflammatory, anti-proliferative and anti-HIV activity.
  • HY-W013332A
    3-Deazaadenosine hydrochloride
    5+ Cited Publications

    		 HIV Infection Inflammation/Immunology
    3-Deazaadenosine (hydrochloride) is an inhibitor of S-adenosylhomocysteine hydrolase, with a Ki of 3.9 µM; 3-Deazaadenosine has anti-inflammatory, anti-proliferative and anti-HIV activity.
  • HY-79511
    FAAH-IN-2
    1 Publications Verification

    O-Desmorpholinopropyl Gefitinib

    		 FAAH Autophagy Others
    FAAH-IN-2 (O-Desmorpholinopropyl Gefitinib) is a potent FAAH(fatty acid amide hydrolase) inhibitor extracted from Patent WO/2008/100977A2.
  • HY-B0134AS
    Bestatin-d7 hydrochloride

    Ubenimex-d7 hydrochloride

    		 Isotope-Labeled Compounds Aminopeptidase Bacterial Antibiotic Cancer Infection
    Bestatin-d7 (hydrochloride) is deuterium labeled Bestatin (hydrochloride). Bestatin hydrochloride is an inhibitor of CD13 (Aminopeptidase N)/APN and leukotriene A4 hydrolase, used for cancer research.
  • HY-15250
    JZL195
    2 Publications Verification

    		 FAAH MAGL Autophagy Neurological Disease
    JZL195 is a selective and efficacious dual fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) inhibitor with IC50s of 2 and 4 nM, respectively.
  • HY-120215
    KT203

    		MAGL Metabolic Disease
    KT203 is a potent and selective inhibitor of α/β-hydrolase domain containing 6 (ABHD6), with an IC50 of 0.31 nM in Neuro2A cells.
  • HY-B0134
    Bestatin
    5+ Cited Publications

    Ubenimex

    		 Aminopeptidase Bacterial Antibiotic Cancer Infection
    Bestatin is a natural, broad-spectrum, and competitive CD13 (Aminopeptidase N)/APN and leukotriene A4 hydrolase inhibitor. Bestatin has anticancer effects.
  • HY-P2877
    Tannase

    		Endogenous Metabolite Others
    Tannase, also known as tanninyl hydrolase, is an enzyme that can hydrolyze ester bonds and tannic acid side bonds, releasing glucose and gallic acid, and is outstanding in clarifying wine and fruit juice.
  • HY-120177
    KT182

    		MAGL Others
    KT182 is a potent and selective inhibitor of α/β-hydrolase domain containing 6 (ABHD6), with an IC50 of 0.24 nM in Neuro2A cells.
  • HY-123863
    SSR411298

    		FAAH Neurological Disease
    SSR411298 is an orally active, selective and reversible fatty acid amide hydrolase (FAAH) inhibitor. SSR411298 has the potential for post-traumatic stress disorder research.
  • HY-B2193
    α-Amylase

    		Others Others
    α-Amylase is a hydrolase enzyme that catalyses the hydrolysis of internal α-1, 4-glycosidic linkages in starch to yield products like glucose and maltose.
  • HY-153523
    Hi 76-0079

    NNC0076-0079; 76-0079

    		 Others Metabolic Disease
    Hi 76-0079 (Compound 31) is a hormone-sensitive lipase (HSL) inhibitor with an IC50 of 184 nM.
  • HY-12989
    LDN-91946

    		Deubiquitinase Cancer Neurological Disease
    LDN-91946 is a potent, selective and uncompetitive ubiquitin C-terminal hydrolase-L1 (UCH-L1) inhibitor with a Ki app of 2.8 μM.
  • HY-147732
    sEH inhibitor-4

    		Epoxide Hydrolase Inflammation/Immunology
    Intensive structural modification resulted in the identification of compound B15 as an effective sEH inhibitor with a value of 0.03 ± 0.01 nm, and the presence of soluble epoxide hydrolase (SEH) can reduce inflammation and pain.
  • HY-129121
    ML-​226

    		MAGL Neurological Disease
    ML226 is a potent α/β hydrolase domain-containing protein 11 (ABHD11) inhibitor in vitro and in situ with IC50s of 15 and 0.68 nM, respectively.
  • HY-125967
    AM 374

    		FAAH Neurological Disease
    AM 374 is an fatty acid amide hydrolase (FAAH) inhibitor. AM 374 inhibits amidase activity with an IC50 value of 13 nM. AM 374 can be used for the research of neurological disease.
  • HY-14595
    Biochanin A
    5+ Cited Publications

    4-Methylgenistein; Olmelin

    		 FAAH Autophagy Endogenous Metabolite Neurological Disease Cancer
    Biochanin A is a naturally occurring fatty acid amide hydrolase (FAAH) inhibitor, which inhibits FAAH with IC50s of 1.8, 1.4 and 2.4 μM for mouse, rat, and human FAAH, respectively.
  • HY-145147
    AAA-10

    		Bacterial Infection
    AAA-10 is an orally active gut bacterial bile salt hydrolases (BSH) inhibitor, with IC50s of 10 nM, 80 nM against B. theta rBSH and B. longum rBSH respectively.
  • HY-145147A
    AAA-10 formic

    		Bacterial Infection
    AAA-10 formic is an orally active gut bacterial bile salt hydrolases (BSH) inhibitor, with IC50s of 10 nM, 80 nM against B. theta rBSH and B. longum rBSH, respectively.
  • HY-W013989
    1,3-Dicyclohexylurea

    		Epoxide Hydrolase Cardiovascular Disease
    1,3-Dicyclohexylurea (DCU) is an orally active and potent sEH (soluble epoxide hydrolase) inhibitor. Oral Delivery of 1,3-Dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive Rats.
  • HY-116793
    Dimepiperate

    MY 93; Yukamate

    		 MAGL Others
    Dimepiperate (MY 93) is a thiocarbamate (TC) pesticide. Dimepiperate has potential off-targets effect for the inhibition of ABHD6.
  • HY-147519
    ARUK3001185

    		Wnt Cancer
    ARUK3001185 (Compound 8l) is a potent, selective, orally active and brain-penetrant inhibitor of Notum activity with an IC50 of 6.7 nM.
  • HY-148573
    sEH inhibitor-14

    		Epoxide Hydrolase Metabolic Disease Inflammation/Immunology Cardiovascular Disease
    sEH inhibitor-14 (compound 33) is a benzoxazolone-5-urea analogue. In addition, sEH inhibitor-14 is a soluble Epoxide Hydrolase (sEH) inhibitor (IC50=0.39 nM).
  • HY-146341
    FAAH-IN-5

    		FAAH MAGL Neurological Disease
    FAAH-IN-5 (Compound 7) is a relative selective, irreversible fatty acid amide hydrolase (FAAH) inhibitor with an IC50 of 10.5 nM. FAAH-IN-5 shows low PAMPA (Parallel Artificial Membrane Permeability Assay) permeability.
  • HY-18081
    PF 750

    		FAAH Autophagy Metabolic Disease
    PF 750 is a selective and covalent fatty acid amide hydrolase (FAAH) inhibitor, with IC50s varied from 16.2-595 nM in different pre-incubation times. Covalently modifies the enzyme’s active site serine nucleophile.
  • HY-16658B
    Z-VAD-FMK
    Maximum Cited Publications
    250 Publications Verification

    Z-VAD(OH)-FMK

    		 Caspase Cancer
    Z-VAD-FMK (Z-VAD(OH)-FMK) is a well-know pan caspase inhibitor, which does not inhibit ubiquitin carboxy-terminal hydrolase L1 (UCHL1) activity even at concentrations as high as 440 μM.
  • HY-119283
    MAGL-IN-5
    1 Publications Verification

    CAY10499

    		 MAGL FAAH Metabolic Disease
    MAGL-IN-5 (CAY10499) is a non-selective lipase inhibitor with IC50 values of 144, 90, and 14 nM for human recombinant monoacylglycerol lipase(MAGL),hormone sensitive lipase(HSL), and fatty acid amide hydrolase(FAAH) respectively.
  • HY-10442
    3-Deazaneplanocin A

    DZNep; 3-Deazaneplanocin

    		 Histone Methyltransferase Orthopoxvirus Cancer Infection
    3-Deazaneplanocin A (DZNep) is a potent histone methyltransferase EZH2 inhibitor. 3-Deazaneplanocin A is a potent S-adenosylhomocysteine hydrolase (AHCY) inhibitor. 3-Deazaneplanocin A shows anti-orthopoxvirus activity.
  • HY-P2875
    Hemicellulase

    		Endogenous Metabolite Others
    Hemicellulase belongs to the enzyme family of glycoside hydrolase, which is often used in biochemical research. Hemicellulase can disrupt the binding of glucose and polymers present in plant fibers to water molecules, and is a key component in the degradation of plant biomass and carbon flow in nature.
  • HY-P2775
    β-Glucosidase

    		Glucosidase Others
    β-Glucosidase is the rate-limiting enzyme of degradation of cellulose. β-Glucosidase is a major group among glycoside hydrolases. β-Glucosidase is involved in the degradation of cellulose in soils and has potential for monitoring biological soil quality.
  • HY-123055
    Adenosine dialdehyde

    		Nucleoside Antimetabolite/Analog Cancer
    Adenosine dialdehyde, a purine nucleoside analogue, is a potent inhibitor of S-Adenosylhomocysteine hydrolase (SAHH) (Ki=3.3 nM). Adenosine Dialdehyde exhibits potent anti-tumor activity in vivo and can be used for the cancer research.
  • HY-10990
    Abexinostat
    5 Publications Verification

    CRA 024781; PCI-24781

    		 HDAC Cancer
    Abexinostat (CRA 024781) is a novel pan-HDAC inhibitor mostly targeting HDAC1 with Ki of 7 nM. Abexinostat also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) hydrolase activity with an EC50 below 10 nM.
  • HY-134354
    pNP-ADPr

    ADP-ribose-pNP

    		 Poly(ADP-ribose) Glycohydrolase (PARG) Others
    pNP-ADPr is a colorimetric substrate that used for the first continuous Poly(ADP-ribose) glycohydrolase (PARG) and ADP-ribosyl hydrolase 3 (ARH3) activity assays. pNP-ADPr can be used for the research of poly(ADP-ribose)polymerase (PARP) enzymes.
  • HY-13322
    Pracinostat
    5+ Cited Publications

    SB939

    		 HDAC Apoptosis Cancer
    Pracinostat is a potent histone deacetylase (HDAC) inhibitor, with IC50s of 40-140 nM, used for cancer research. Pracinostat also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) hydrolase activity with an EC50 below 10 nM.
  • HY-150226
    Enzyme-IN-1

    		Proteasome Inflammation/Immunology
    Enzyme-IN-1 (compound 1) is a peptide-based inhibitor of N-terminal nucleophile (Ntn) hydrolases. Specifically, Enzyme-IN-1 inhibits the chymotrypsin-like activity (CT-L) of the 20S proteasome. Enzyme-IN-1 may has potential antiinflammatory properties.
  • HY-120252
    ABC44

    		Others Neurological Disease
    ABC44 is a potent serine hydrolase inhibitor with IC50s of 0.1 μM and 6.5 μM for palmitoyl protein thioesterase 1 (PPT1) in situ and in vitro, respectively. ABC44 can be used for researching infantile neuronal ceroid lipofuscinosis.
  • HY-134354A
    pNP-ADPr disodium

    ADP-ribose-pNP disodium

    		 Poly(ADP-ribose) Glycohydrolase (PARG) Others
    pNP-ADPr disodium is a colorimetric substrate that used for the first continuous Poly(ADP-ribose) glycohydrolase (PARG) and ADP-ribosyl hydrolase 3 (ARH3) activity assays. pNP-ADPr disodium can be used for the research of poly(ADP-ribose)polymerase (PARP) enzymes.
  • HY-155029
    sEH inhibitor-16

    		Epoxide Hydrolase Inflammation/Immunology
    sEH inhibitor-16 is a soluble epoxide hydrolase (sEH) inhibitors with an IC50 of 2 nM. sEH inhibitor-16 reduces the inflammatory damage in Cerulein (HY-A0190)-induced acute pancreatitis (AP) in mice and can be used for inflammation/immunology research.
  • HY-118158
    FAAH/MAGL-IN-4

    		FAAH Neurological Disease
    FAAH/MAGL-IN-4 (Compound 13) is a potent fatty acid amide hydrolase (FAAH) and monoglyceride lipase (MGL) inhibitor with IC50s of 9.1 nM and 7.9 μM, respectively. FAAH/MAGL-IN-4 can be used for the research of pain and CNS disorders.
  • HY-137824
    4-Methylumbelliferyl-β-D-xylopyranoside

    4-Methylumbelliferyl-β-D-xyloside

    		 Others Others
    4-Methylumbelliferyl-β-D-xylopyranoside (MuX) can be used as substrate for the research of β-Xylosidase activity. 4-Methylumbelliferyl-β-D-xylopyranoside shows burst, steady-state kinetics, which supports the conclusion that hydrolysis of the glycosidic bonds for the substrate 4-Methylumbelliferyl-β-D-xylopyranoside is rapid.
  • HY-P2831
    Carboxylesterase

    CESs

    		 Endogenous Metabolite Metabolic Disease
    Carboxylesterases (CESs), namely carboxylate hydrolases, are widely distributed in nature, commonly found in mammalian liver, and often used in biochemical research. Carboxylesterase catalyzes the hydrolysis of a variety of endogenous and exogenous substrates, including esters, thioesters, carbamates, and amides, hydrolyzing carboxylic acid esters to the corresponding alcohols and carboxylic acids.
  • HY-12186
    3-Deazaneplanocin A hydrochloride
    20+ Cited Publications

    DZNep hydrochloride; NSC 617989 hydrochloride; 3-Deazaneplanocin hydrochloride

    		 Histone Methyltransferase Orthopoxvirus Cancer Infection
    3-Deazaneplanocin A hydrochloride (DZNep hydrochloride) is a potent histone methyltransferase EZH2 inhibitor. 3-Deazaneplanocin A hydrochlorideis a potent S-adenosylhomocysteine hydrolase (AHCY) inhibitor. 3-Deazaneplanocin A hydrochloride also has anti-orthopoxvirus and anti-variola activities.
  • HY-18637
    LDN-57444
    10+ Cited Publications

    		 Deubiquitinase Apoptosis Neurological Disease
    LDN-57444 is a reversible, competitive and site-directed inhibitor of ubiquitin C-terminal hydrolase L1 (UCH-L1), with an IC50 of 0.88 μM and a Ki of 0.40 μM; LDN-57444 also suppresses UCH-L3 activity, with an IC50 of 25 μM.
  • HY-145831
    sEH/AChE-IN-1

    		Cholinesterase (ChE) Inflammation/Immunology Neurological Disease
    sEH/AChE-IN-1 (Compound 12a) is a dual inhibitor of the enzymes soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE). sEH/AChE-IN-1 provides cumulative effects against neuroinflammation and memory impairment. sEH/AChE-IN-1 has the potential for the research of Alzheimer's disease (AD).
  • HY-146342
    FAAH/MAGL-IN-3

    		FAAH MAGL Neurological Disease
    FAAH/MAGL-IN-3 (Compound 10) is an irreversible fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) dual inhibitor with IC50 values of 179 and 759 nM against FAAH and MAGL, respectively. FAAH/MAGL-IN-3 shows low PAMPA (Parallel Artificial Membrane Permeability Assay) permeability.
  • HY-145832
    sEH/AChE-IN-2

    		Cholinesterase (ChE) Inflammation/Immunology Neurological Disease
    sEH/AChE-IN-2 (Compound 12b) is a dual inhibitor of the enzymes soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE). sEH/AChE-IN-2 provides cumulative effects against neuroinflammation and memory impairment. sEH/AChE-IN-2 has the potential for the research of Alzheimer's disease (AD).
  • HY-P2840
    Dextranase

    		Endogenous Metabolite Metabolic Disease
    Dextranase, glucan hydrolase, is often used in biochemical research. Dextranase can catalyze the hydrolysis of α-(1,6)-glucosidic bonds in dextran, and has a wide range of applications, such as food processing, sugar modification, agent preparation, and medicine for enhancing the activity of endocarditis antibiotics wait.
  • HY-135747
    Gut restricted-7

    GR-7

    		 Bacterial Infection
    Gut restricted-7 (GR-7) is a potent, covalent and orally active pan-bile salt hydrolase (BSH) inhibitor. Gut restricted-7 has a tissue-selective and is restricted to the gut. Gut restricted-7 decreases gut bacterial BSHs and decreases deconjugated bile acid levels in feces of mice.
  • HY-18977
    KML29
    2 Publications Verification

    		 MAGL Metabolic Disease Inflammation/Immunology
    KML29 is an extremely selective, orally active and irreversible MAGL inhibitor, with IC50 values of 15 nM, 43 nM and 5.9 nM for mouse, rat and human MAGL, respectively. KML29 exhibits minimal cross-reactivity toward other central and peripheral serine hydrolases, including no detectable activity against FAAH.
  • HY-135653A
    (Rac)-EC5026

    (Rac)-BPN-19186

    		 Epoxide Hydrolase Neurological Disease
    (Rac)-EC5026 ((Rac)-BPN-19186) is a potent piperidine inhibitor of soluble epoxide hydrolase (sEH) extracted from patent WO2019156991A1, page 39, has a Ki of 0.06 nM. (Rac)-EC5026 can be used for the research of Parkinson's disease and dementia with Lewy Bodies (DLB).
  • HY-114043
    NCGC00092410

    		Glucosidase Metabolic Disease
    NCGC00092410 is a potent, selective, and nonsugar glucocerebrosidase (GC) inhibitor, with an IC50 of 31 nM. NCGC00092410 shows no activity against the related hydrolases at concentrations up to 77 μM. NCGC00092410, a GC chaperone, and increases the activity and lysosomal localization of glucocerebrosidase in mutant cell lines. NCGC00092410 can be used for the research of Gaucher disease.
  • HY-P3017
    Endo-1,4-β-xylanase

    Xylanase; CtXyn11A; EC 3.2.1.8

    		 Poly(ADP-ribose) Glycohydrolase (PARG) Others
    Endo-1,4-β-xylanase (Xylanase) is an arabinoxylan (AX) degrading enzyme and a glycoside hydrolase, is often used in biochemical studies. Endo-1,4-β-xylanase cleaves the β-xylosidic bond between two d-xylopyranosyl residues linked in β-(1,4).
  • HY-103337
    N-Arachidonoylserotonin

    Arachidonyl serotonin; AA-5-HT

    		 FAAH TRP Channel Neurological Disease
    N-Arachidonoylserotonin (Arachidonyl serotonin; AA-5-HT) is a potent fatty acid amide hydrolase (FAAH) inhibitor with an IC50 value of 1~12 µM. N-Arachidonoylserotonin acts also as an antagonist of transient receptor potential vanilloid-type 1 (TRPV1) channels (IC50=70~100 nM). N-Arachidonoylserotonin is analgesic in rodents .
  • HY-103461
    FAAH-IN-6

    		FAAH Neurological Disease
    FAAH-IN-6 (compound 21d) is a potent, orally active and cross the blood-brain barrier fatty acid amide hydrolase (FAAH) inhibitor with IC50s of 0.72, 0.28 nM for hFAAH, rFAAH, respectively. FAAH-IN-6 shows dose-dependent analgesic efficacy in animal models of both neuropathic and inflammatory pain.
  • HY-16658
    Z-VAD(OMe)-FMK
    140+ Cited Publications

    Z-Val-Ala-Asp(OMe)-FMK

    		 Caspase Cancer
    Z-VAD(OMe)-FMK (Z-Val-Ala-Asp(OMe)-FMK) is a cell-permeable and irreversible pan-caspase inhibitor. Z-VAD(OMe)-FMK is an ubiquitin carboxy-terminal hydrolase L1 (UCHL1) inhibitor. Z-VAD(OMe)-FMK irreversibly modifies UCHL1 by targeting the active site of UCHL1.
  • HY-143294
    sEH inhibitor-2

    		Epoxide Hydrolase Cardiovascular Disease
    sEH inhibitor-2 (compound 5l) is an orally active (predicted percentage absorption: 71.2-88.4%) soluble epoxide hydrolase (sEH) inhibitor, with an IC50 of 0.9 nM. sEH inhibitor-2 can maintain epoxyeicosatrienoic acids (EETs) serum level in high concentrations. sEH inhibitor-2 can be used in study of cardiovascular protection.
  • HY-W024365
    3-tert-Butyl-4-methoxyphenol

    		PROTAC Linkers Cancer
    3-tert-Butyl-4-methoxyphenol is a PROTAC linker, belongs to alkyl/ether class, with insecticidal activity. 3-tert-Butyl-4-methoxyphenol also induced increased activities of glutathione (GSH) S-transferase and epoxide hydrolase in the liver and forestomach tissues of A/HeJ mice, regulating the carcinogen metabolism system.
  • HY-19644
    GSK2256294A
    2 Publications Verification

    GSK 2256294

    		 Epoxide Hydrolase Cardiovascular Disease
    GSK2256294A (GSK 2256294) is a selective and orally active inhibitor of soluble epoxide hydrolase (sEH). GSK2256294A inhibits recombinant human sEH, rat sEH orthologs and murine sEH orthologs with IC50s of 27, 61 and 189 pM, respectively. GSK2256294A can be used for the research of chronic obstructive pulmonary disease (COPD) and cardiovascular disease.
  • HY-146248
    TFMU-ADPr

    		Poly(ADP-ribose) Glycohydrolase (PARG) Others
    TFMU-ADPr is a general substrate for monitoring poly(ADP-ribose) glycohydrolase (PARG) activity. TFMU-ADPr can directly report on total PAR hydrolase activity via release of a fluorophore. TFMU-ADPr has excellent reactivity, generality, stability, and usability. TFMU-ADPr is a versatile tool for assessing small-molecule inhibitors in vitro and probing the regulation of ADP-ribosyl catabolic enzymes.
  • HY-N2512
    1-Monomyristin
    1 Publications Verification

    		 FAAH Bacterial Fungal Endogenous Metabolite Autophagy Infection
    1-Monomyristin, extracted from Serenoa repens, inhibits the hydrolysis of 2-oleoylglycerol (IC50=32 μM) and fatty acid amide hydrolase (FAAH) activity (IC50=18 μM). 1-Monomyristin shows antibacterial activity against Staphylococcus aureus and Aggregatibacter actinomycetemcomitans and also antifungal activity against Candida albicans.
  • HY-113489
    14,15-Epoxyeicosatrienoic acid

    14,15-EET

    		 Others Neurological Disease Cardiovascular Disease
    14,15-Epoxyeicosatrienoic acid (14,15-EET) is a metabolite of Arachidonic acid (HY-109590). 14,15-Epoxyeicosatrienoic acid is a potent inhibitor of in vivo platelet aggregation. 14,15-Epoxyeicosatrienoic acid facilitates astrocytic Aβ clearance. 14,15-Epoxyeicosatrienoic acid can be used for Alzheimer's Disease research.
  • HY-P2233
    Globomycin

    		Bacterial Antibiotic Infection
    Globomycin is a lipopeptide antibiotic and a signal peptidase II (LspA) inhibitor. Globomycin inhibits processing of the prolipoprotein by binding irreversibly to the peptidase. Globomycin has toxic for the mollicute Spiroplasma melliferum with a MIC in the range 6.25-12.5 μM.
  • HY-128171
    Diflapolin
    1 Publications Verification

    		 FLAP Epoxide Hydrolase Inflammation/Immunology
    Diflapolin is a highly active dual 5-lipoxygenase-activating protein (FLAP)/soluble epoxide hydrolase (sEH) inhibitor with marked anti-inflammatory efficacy and high target selectivity. Diflapolin inhibits 5-LOX product formation in intact human monocytes and neutrophils with IC50s of  30 and 170 nM, respectively, and suppressed the activity of isolated sEH (IC50=20 nM).
  • HY-146704
    COX-2/sEH-IN-1

    		Epoxide Hydrolase COX Cardiovascular Disease
    COX-2/sEH-IN-1 (Compound 9c) is an orally active, dual COX-2 and sEH (soluble epoxide hydrolase) inhibitor with IC50 values of 1.24 µM and 0.40 nM against COX-2 and sEH, respectively. COX-2/sEH-IN-1 shows improved anti-inflammatory activity and highly reduced cardiovascular risks.
  • HY-P2871
    α-Galactosidase

    EC 3.2.1.22

    		 Endogenous Metabolite Others
    α-Galactosidase (EC 3.2.1.22), that is, α-galactosidase, is a glycoside hydrolase that widely exists in animals, plants and microorganisms, and is often used in biochemical research. α-Galactosidase catalyzes the hydrolysis of α-1,6-linked terminal galactose residues, including galactooligosaccharides, galactomannans, and galactolipids. Catalyzes many catabolic processes including cleavage of glycoproteins, glycolipids and polysaccharides.
  • HY-135795
    1-Cyclohexyl-3-dodecyl urea

    CDU; N-Cyclohexyl-N-dodecyl urea; NCND

    		 Epoxide Hydrolase Metabolic Disease Cardiovascular Disease
    1-Cyclohexyl-3-dodecyl urea (CDU; N-Cyclohexyl-N-dodecyl urea; NCND) is a highly selective soluble epoxide hydrolase (sEH) inhibitor. 1-Cyclohexyl-3-dodecyl urea (CDU; N-Cyclohexyl-N-dodecyl urea; NCND) increases epoxyeicosatrienoic acids (EETs) levels and lowers blood pressure in angiotensin II (Ang II) hypertension.
  • HY-146248A
    TFMU-ADPr triethylamine

    		Poly(ADP-ribose) Glycohydrolase (PARG) Others
    TFMU-ADPr triethylamine is a general substrate for monitoring poly(ADP-ribose) glycohydrolase (PARG) activity. TFMU-ADPr triethylamine can directly report on total PAR hydrolase activity via release of a fluorophore. TFMU-ADPr triethylamine has excellent reactivity, generality, stability, and usability. TFMU-ADPr triethylamine is a versatile tool for assessing small-molecule inhibitors in vitro and probing the regulation of ADP-ribosyl catabolic enzymes.
  • HY-116815
    Lalistat 1

    		Bacterial Infection Neurological Disease
    Lalistat 1 is a potent, selective, and competitive inhibitor of lysosomal acid lipase (LAL) and against purified human LAL (phLAL) with an IC50 of 68 nM. Lalistat 1 is a inhibitor of immunoglobulin A1 protease (IgA1P) proteases for H. influenzae, has less effects on other serine hydrolases (trypsin or β-lactamase, etc.). Lalistat 1 can be used for the research of niemann-pick type C (NPC) disease.
  • HY-151616
    sEH inhibitor-10

    		Epoxide Hydrolase Metabolic Disease Inflammation/Immunology Cardiovascular Disease
    sEH inhibitor-10 (Compound 37) is a selective soluble epoxide hydrolase (sEH) inhibitor (IC50=0.5 μM). sEH inhibitor-10 maintains high cycloeicosatrienoic acid (EETs) levels by inhibiting sEH, thereby reducing inflammation, regulating endothelial tone, improving mitochondrial function, and reducing oxidative stress. sEH inhibitor-10 has good research potential in metabolic, renal and cardiovascular diseases.
  • HY-P2869
    β-Galactosidase

    		Endogenous Metabolite Others
    β-Galactosidase is a glycoside hydrolase that hydrolyzes the β-glycosidic bonds formed between galactose and its organic moieties. In E.coli, the lacZ gene is the structural gene of β-galactosidase, which can be used as part of the induction system lac operon. β-Galactosidase can hydrolyze lactose to form glucose and galactose, and enter glycolysis; it can also catalyze the transgalactosylation of lactose into allolactose; allolactose can be cracked into monosaccharides.
  • HY-P2797
    Chitinase

    AMCase

    		 Bacterial Metabolic Disease Inflammation/Immunology
    Chitinase has partial lysozyme activity and is widely found in bacteria, fungi, animals and some plants. Chitinase belongs to the glycosyl hydrolase family. Chitinase catalyzes chito-oligosaccharide hydrolysis. Chitinases also can serve as prognostic biomarkers of disease progression. Chitinase can be used in the research of pathogenesis of various human fibrotic and inflammatory disorders, particularly those of the lung (idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, sarcoidosis, and asthma) and the gastrointestinal tract (inflammatory bowel diseases (IBDs) and colon cancer).
  • HY-152148
    JZP-MA-11

    		MAGL Neurological Disease
    JZP-MA-11 is a positron emission tomography (PET) ligand targeting the endocannabinoid α/β-hydrolase domain 6 (ABHD6) enzyme. JZP-MA-11 selectively inhibits ABHD6 with an IC50 value of 126 nM. JZP-MA-11 can cross the blood-brain barrier (BBB). [18F]JZP-MA-11 has the potential for preclinical evaluation targeting the brain ABHD6 in mice and nonhuman primate (NHP).
  • HY-E70033
    D-galactosyl-β1-3-N-acetyl-D-hexosamine phosphorylase (BiGalHexNAcP)

    		Endogenous Metabolite Metabolic Disease
    D-galactosyl-β1-3-N-acetyl-D-hexosamine phosphorylase (BiGalHexNAcP) is a member of CAZy glycoside hydrolase GH112 family, is often used in biochemical studies. D-galactosyl-β1-3-N-acetyl-D-hexosamine phosphorylase (BiGalHexNAcP) catalyses the phosphorolysis of lacto-n-biose and galacto-n-biose, to produce Gal-1-P and the corresponding N-acetyl-D-hexosamine.
  • HY-121422
    JZP-361

    		MAGL Histamine Receptor Inflammation/Immunology
    JZP-361 is a potent, reversible and selective inhibitor of human recombinant MAGL (hMAGL) with an IC50 of 46 nM. JZP-361 also shows antihistaminergic activities and can be used for asthma research.